Clinical trial
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small…
NCT00132379 · Active Biotech AB, Industry · Completed
Key facts
| NCT number | NCT00132379 |
|---|---|
| Title | ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer |
| Official title | An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Active Biotech AB, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | ABR-217620, docetaxel |
| Enrollment | 13 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Aug 22, 2005 |
| Last update posted | Aug 27, 2014 |
| Countries | Denmark, Russia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: